How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

22,403 results for

Insulin Dosing

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

141. Comparison of the Efficacy and Safety of Two Different Dose Adjustment Regimens for Insulin Degludec/Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Previously Treated With Insulin Glargine

Comparison of the Efficacy and Safety of Two Different Dose Adjustment Regimens for Insulin Degludec/Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Previously Treated With Insulin Glargine Comparison of the Efficacy and Safety of Two Different Dose Adjustment Regimens for Insulin Degludec/Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Previously Treated With Insulin Glargine - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer (...) to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Comparison of the Efficacy and Safety of Two Different Dose Adjustment Regimens for Insulin Degludec/Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Previously Treated With Insulin Glargine (BOOST®) The safety and scientific validity of this study

2012 Clinical Trials

142. Single Dose Clamp Study to Evaluate Concentration-time Profile and Metabolic Activity of 3 Dose Levels of Afrezza and 3 Dose Levels of Insulin Lispro in Patients With Type 1 Diabetes Mellitus

for Study: All Accepts Healthy Volunteers: No Criteria Inclusion criteria : Male or female patients, between 18 and 65 years of age, inclusive, with diabetes mellitus type 1 for more than one year, as defined by the American Diabetes Association. Total insulin dose of <1.0 U/kg/day. Body weight between 50.0 and 95 kg, inclusive, body mass index between 18.5 and 29 kg/m², inclusive. Fasting serum C-peptide <0.3 nmol/L. Glycohemoglobin (HbA1c) ≤75 mmol/mol (≤9%). Stable insulin regimen for at least 2 (...) Single Dose Clamp Study to Evaluate Concentration-time Profile and Metabolic Activity of 3 Dose Levels of Afrezza and 3 Dose Levels of Insulin Lispro in Patients With Type 1 Diabetes Mellitus Single Dose Clamp Study to Evaluate Concentration-time Profile and Metabolic Activity of 3 Dose Levels of Afrezza and 3 Dose Levels of Insulin Lispro in Patients With Type 1 Diabetes Mellitus - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting

2015 Clinical Trials

143. High-strength insulins: think and act in units of insulin to prevent errors

High-strength insulins: think and act in units of insulin to prevent errors FEATURED REVIEW At home as in hospital (and other healthcare facilities), errors associated with insulin use are numerous, frequent and can have serious consequences. How can dosing errors due to the coexistence of different strengths of insulin on the market be prevented? Full review (2 pages) available for download by subscribers. Abstract The coexistence of different strengths of insulin (100 units/ml, 200 units/ml (...) and 300 units/ml) on the market can lead to dosing errors, sometimes with serious consequences. These errors are due to: attempts at dose conversion that are actually unnecessary; prescribing errors; use of an insulin syringe to draw up solution from a pen cartridge; and differences between pens in the number of units of insulin per dose step. When selecting the dose on an insulin pen, the number displayed on the dose counter always corresponds to the number of units of insulin to be administered

2019 Prescrire

144. Insulin Dosing in Type 1 Diabetes

): 50% of total ( ) once daily or twice daily (rapid acting): 50% of total Rapid acting s: , Divide out equally before meals Adjust later for carb count variations at meals IV. Management: Adjustments See for adjustment regimen Images: Related links to external sites (from Bing) These images are a random sampling from a Bing search on the term "Insulin Dosing in Type 1 Diabetes." Click on the image (or right click) to open the source website in a new browser window. Related Studies (from Trip (...) Insulin Dosing in Type 1 Diabetes Insulin Dosing in Type 1 Diabetes Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Insulin Dosing

2018 FP Notebook

145. Insulin Dosing in Type 2 Diabetes

) ( ) ( ) ( ) Step 3: Starting dose <8 Basal 0.1 units/kg once daily AND 0.1 units/kg divided equally before meals (start before breakfast and dinner) 8-10 Basal 0.2 units/kg once daily AND 0.2 units/kg divided equally before meals (start before breakfast and dinner) >10 Basal 0.3 units/kg once daily AND 0.3 units/kg divided equally before meals (start before breakfast and dinner) VII. Protocol: Starting Basal/Bolus Insulin using NPH Background Other regimens less complicated and therefore preferred However, NPH (...) : Starting Insulin using Premixed Insulin Step 0: Adjust oral medications Stop ( , ) Continue sensitizers ( , ) preparations (for twice daily dosing) Mix 75/25 or Premix 70/30 Starting dose Based on Regimen ( Augmentation) as above Divide current basal dose into 2/3 AM and 1/3 PM or Divide current basal dose into 1/2 AM and 1/2 PM Based on current A1C <8: 0.1 units/kg in AM and 0.1 units/kg in PM A1C 8-10: 0.2 units/kg in AM and 0.2 units/kg in PM A1C >10: 0.3 units/kg in AM and 0.3 units/kg in PM

2018 FP Notebook

146. Carbohydrate Count in Insulin Dosing

Carbohydrate Count in Insulin Dosing Carbohydrate Count in Insulin Dosing Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Carbohydrate (...) Count in Insulin Dosing Carbohydrate Count in Insulin Dosing Aka: Carbohydrate Count in Insulin Dosing , Insulin Adjustment with Carbohydrate Counting From Related Chapters II. Management: Step 1a - Determine Carbohydrate to Insulin ratio Determine total used per day Option 1: Known dose from multiple daily doses or Option 2: Calculate based on patient weight Type I: Total daily (TDI) TDI = WtKg x 0.1 to 0.3 units/kg (start low) Type I: Total basal dose (TBD) TBD = WtKg x 0.2 TBD = 0.4 x Total Daily

2018 FP Notebook

147. Insulin Dosing

Insulin Dosing Insulin Dosing Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Insulin Dosing Insulin Dosing Aka: Insulin Dosing From (...) for consistent pattern in s for >3 days Compare for same time each day For each time of day: Calculate range Calculate median Consider eating and activity patterns during day Ignore spurious values Adjust only one dose at a time Correct first Correct highest s next Maintain a 50:50 mix of Basal to VI. Evaluation: Adjustment of Insulin Adjustment factors (for lows and highs) Adjust in small steps at a time Adjustment steps based on amount dose <10 units: Adjust by 1 unit dose 10-20 units: Adjust by 2 units

2018 FP Notebook

148. Effects of high-dose oral insulin on immune responses in children at high risk for type 1 diabetes: the Pre-POINT randomized clinical trial. Full Text available with Trip Pro

Effects of high-dose oral insulin on immune responses in children at high risk for type 1 diabetes: the Pre-POINT randomized clinical trial. Exposing the oral mucosa to antigen may stimulate immune tolerance. It is unknown whether treatment with oral insulin can induce a tolerogenic immune response in children genetically susceptible to type 1 diabetes.To assess the immune responses and adverse events associated with orally administered insulin in autoantibody-negative, genetically at-risk (...) children.The Pre-POINT study, a double-blind, placebo-controlled, dose-escalation, phase 1/2 clinical pilot study performed between 2009 and 2013 in Germany, Austria, the United States, and the United Kingdom and enrolling 25 islet autoantibody-negative children aged 2 to 7 years with a family history of type 1 diabetes and susceptible human leukocyte antigen class II genotypes. Follow-up was completed in August 2013.Children were randomized to receive oral insulin (n = 15) or placebo (n = 10) once daily

2015 JAMA Controlled trial quality: predicted high

149. Efficacy and safety of once-daily insulin degludec dosed flexibly at convenient times vs fixed dosing at the same time each day in a Japanese cohort with type 2 diabetes: A randomized, 26-week, treat-to-target trial. Full Text available with Trip Pro

Efficacy and safety of once-daily insulin degludec dosed flexibly at convenient times vs fixed dosing at the same time each day in a Japanese cohort with type 2 diabetes: A randomized, 26-week, treat-to-target trial. This trial assessed the efficacy and safety of the possibility of varying the daily injection time of once-daily, long-acting basal insulin degludec (IDeg) in Japanese patients with type 2 diabetes inadequately controlled with insulin glargine.This was a 26-week, multicenter, open (...) -label, randomized, treat-to-target trial, with a 2 × 2 factorial design comparing IDeg flexible (allowing dosing ±8 h from an agreed dosing time) with IDeg fixed dosing (at the same time each day). It was carried out in 458 adult patients who were inadequately controlled on insulin glargine with or without oral antidiabetic drugs.The majority of doses were taken within 2 h of the agreed dosing time, showing a high level of adherence among Japanese patients. After 26 weeks, IDeg flexible was non

2016 Journal of Diabetes Investigation Controlled trial quality: uncertain

150. Comparison of Standard vs Higher Starting Dose of Insulin Glargine in Chinese Patients With Type 2 Diabetes (Glargine Starting Dose)

: Standard initial dose of insulin glargine Dose 1 of insulin glargine will be administered subcutaneously once a day at the same time every day. Previous non-sulfonylurea OADs (eg, metformin, acarbose) are background treatment and will be continued at the same dosage and dosing frequency as before. Drug: INSULIN GLARGINE Pharmaceutical form: solution Route of administration: subcutaneous injection Other Name: HOE901 Drug: metformin Pharmaceutical form: table or capsule Route of administration: oral (...) administration Drug: acarbose Pharmaceutical form: table or capsule Route of administration: oral administration Experimental: Higher initial dose of insulin glargine Dose 2 of insulin glargine will be administered subcutaneously once a day at the same time every day. Previous non-sulfonylurea OADs (eg, metformin, acarbose) are background treatment and will be continued at the same dosage and dosing frequency as before. Drug: INSULIN GLARGINE Pharmaceutical form: solution Route of administration

2016 Clinical Trials

151. Effect of one time high dose "stoss therapy" of vitamin D on glucose homeostasis in high risk obese adolescents. Full Text available with Trip Pro

Effect of one time high dose "stoss therapy" of vitamin D on glucose homeostasis in high risk obese adolescents. To study the effect of using a one time high dose "stoss therapy" of vitamin D2 (ergocalciferol: VD2) on indices of insulin sensitivity {whole body sensitivity index: WBISI} and secretion {insulinogenic index: IGI} measured during an oral glucose tolerance test (OGTT) in obese adolescents with VDD (25 OHD; serum metabolite of vit D: < 30 ng/dL).In a randomized placebo controlled (...) respectively.Adolescents were obese and insulin resistant (mean ± SD: mean age = 15.1 ± 1.9 years; BMI: 32.7 ± 9.8; homeostatic model of insulin resistance: HOMA-IR: 4.2 ± 2.8). Stoss therapy with VD2 increased 25OHD from baseline (16.7 ± 2.9 to 19.5 ± 4.5; p = 0.0029) when compared to the placebo. WBISI (2.8 ± 1.9) showed a trend towards improvement in Rx group (p = 0.0577) after adjustment for covariates. IGI (3 ± 2.2) showed an improvement in both Rx and placebo groups.Our study demonstrated that using a high dose

2018 Archives of endocrinology and metabolism Controlled trial quality: uncertain

152. Sotagliflozin for adult patients with Type 1 Diabetes Mellitus who have inadequate blood glucose control using insulin or insulin analogues

%. The recommended treatment approach is intensive insulin therapy using multi- ple subcutaneous insulin doses or continuous subcutaneous insulin infusion (CSII) using a personal insulin pump. (A) •A key element of therapy for diabetes type 1 is the patient’s ability to modify insulin doses based on carbohydrate meal content, baseline blood glucose level, and planned physical activity. Knowledge of the effect of protein and fat on blood glucose level is also important for optimization of insulin dosage. (E (...) Medicinal Products BG Blood Glucose BHB B-HydroxyButyrate BMI Body Mass Index CI Confidence Interval CFB Capillary Finger-stick Blood CFB Change From Baseline CGM Continuous Glucose Monitoring CHMP Committee for Medicinal Products for Human use CrI Credible Interval CSII Continuous Subcutaneous Insulin Infusion CSR Clinical Study Report CTR Clinical Trials Register CVD Cardiovascular Disease DBP Diastolic Blood Pressure DDG Deutsche Diabetes Gesellschaft DDS2 Diabetes Distress Screening Scale DIC

2019 EUnetHTA

153. Influence of initial insulin dosage on blood glucose dynamics of children and adolescents with newly diagnosed type 1 diabetes mellitus. Full Text available with Trip Pro

Influence of initial insulin dosage on blood glucose dynamics of children and adolescents with newly diagnosed type 1 diabetes mellitus. To investigate the effect of initial insulin dosage on blood glucose (BG) dynamics, β-cell protection, and oxidative stress in type 1 diabetes mellitus.Sixty newly diagnosed type 1 diabetes mellitus patients were randomly assigned to continuous subcutaneous insulin infusions of 0.6 ± 0.2 IU/kg/d (group 1), 1.0 ± 0.2 IU/kg/d (group 2), or 1.4 ± 0.2 IU/kg/d (...) (group 3) for 3 wk. BG was monitored continuously for the first 10 d and the last 2 d of wk 2 and 3. A total of 24-hour urinary 8-iso-PGF2α was assayed on days 8, 9, and 10. The occurrence and duration of the honeymoon period were recorded. Fasting C-peptide and glycosylated hemoglobin (HbA1c) were assayed after 1, 6, and 12 months of insulin treatment.BG decreased to the target range by the end of wk 3 (group 1), wk 2 (group 2), or wk 1 (group 3). The actual insulin dosage over the 3 wk, frequency

2017 Pediatric diabetes Controlled trial quality: uncertain

154. Computer-determined dosage of insulin in the management of neonatal hyperglycaemia (HINT2): protocol of a randomised controlled trial. Full Text available with Trip Pro

Computer-determined dosage of insulin in the management of neonatal hyperglycaemia (HINT2): protocol of a randomised controlled trial. Neonatal hyperglycaemia is frequently treated with insulin, which may increase the risk of hypoglycaemia. Computer-determined dosage of insulin (CDD) with the STAR-GRYPHON program uses a computer model to predict an effective dose of insulin to treat hyperglycaemia while minimising the risk of hypoglycaemia. However, CDD models can require more frequent blood (...) , at least 4 hours apart) will be randomised to one of three groups: (1) CDD using the STAR-GRYPHON model-based decision support system: insulin dose and frequency of blood glucose testing advised by STAR-GRYPHON, with a maximum testing interval of 4 hours; (2) bedside titration: insulin dose determined by medical staff, maximum blood glucose testing interval of 4 hours; (3) standard care: insulin dose and frequency of blood glucose testing determined by medical staff. The target range for blood glucose

2017 BMJ open Controlled trial quality: predicted high

155. Treatment of Pre-pubertal Patients with Growth Hormone Deficiency: Patterns in Growth Hormone Dosage and Insulin-like Growth Factor-I Z-scores Full Text available with Trip Pro

Treatment of Pre-pubertal Patients with Growth Hormone Deficiency: Patterns in Growth Hormone Dosage and Insulin-like Growth Factor-I Z-scores To describe the range of insulin-like growth factor-I (IGF-I) z-score values (IGF-Iz) and growth hormone (GH) dose adjustments in pre-pubertal patients with GH deficiency (GHD) treated with GH in a single tertiary care center.This is a retrospective review of GH-treated patients of ages ≤9 years with GHD, seen in an endocrinology clinic in 2013-2014 (...) . Patient demographics and pre-treatment anthropometrics, GH treatment duration, IGF-Iz, and GH dosage (mg/kg/week) were extracted. Multipredictor linear regression was used to evaluate the associations between IGF-Iz and GH dosage and subject gender, race, insurance type, age, and clinical characteristics. Logistic regression was used to calculate the odds ratio of direction of GH dose adjustment (decrease/no change versus increase) and IGF-Iz category based on patient clinical characteristics

2017 Journal of clinical research in pediatric endocrinology

156. Patient-reported outcomes in transition from high-dose U-100 insulin to human regular U-500 insulin in severely insulin-resistant patients with type 2 diabetes: analysis of a randomized clinical trial. Full Text available with Trip Pro

Patient-reported outcomes in transition from high-dose U-100 insulin to human regular U-500 insulin in severely insulin-resistant patients with type 2 diabetes: analysis of a randomized clinical trial. Initiation and titration of human regular U-500 insulin (U-500R) with a dosing algorithm of either thrice daily (TID) or twice daily (BID) improved glycemic control with fewer injections in patients with type 2 diabetes treated with high-dose, high-volume U-100 insulin. The objective (...) and BID groups (and no differences between TID and BID groups) from baseline to endpoint. VAS-ISP scores improved for both treatment groups (-5.60 TID; -6.47 BID; p < .05 for both) from baseline to endpoint.U500 can be successfully titrated for improved glycemic control using BID and TID regimens with diabetes-specific Patient-Reported Outcomes showing improvements in both arms; however, BID had better scores than TID in overall, treatment burden, daily life, and compliance domains.These secondary

2016 Health and quality of life outcomes Controlled trial quality: uncertain

157. Improving management of type 1 diabetes in the UK: the Dose Adjustment For Normal Eating (DAFNE) programme as a research test-bed Full Text available with Trip Pro

Improving management of type 1 diabetes in the UK: the Dose Adjustment For Normal Eating (DAFNE) programme as a research test-bed Improving management of Type 1 diabetes in the UK: the Dose Adjustment for Normal Eating (DAFNE) programme as a research test-bed. A mixed method analysis of the barriers and facilitators to successful diabetes self management, a health economic analysis, a cluster RCT of different models of delivery of an educational intervention and the potential of insulin pumps

2014 NIHR HTA programme

158. Insulin degludec requires lower bolus insulin doses than does insulin glargine in Japanese diabetic patients with insulin-dependent state. Full Text available with Trip Pro

Insulin degludec requires lower bolus insulin doses than does insulin glargine in Japanese diabetic patients with insulin-dependent state. The study presents a comparison of the glucose-lowering effects, glycemic variability, and insulin doses during treatment with insulin degludec or insulin glargine.In this open-label, single-center, 2-way crossover study, 13 Japanese diabetic outpatients in the insulin-dependent state on basal-bolus therapy were assigned to receive either insulin glargine (...) followed by insulin degludec, or insulin degludec followed by insulin glargine. Basal insulin doses were fixed in principle, and patients self-adjusted their bolus insulin doses. Seventy-two-hour continuous glucose monitoring was performed 2 weeks after switching the basal insulin.Mean blood glucose (mg/dL) was not significantly different between insulin degludec and insulin glargine over 48 hours (141.8 ± 35.2 vs 151.8 ± 43.3), at nighttime (125.6 ± 40.0 vs 124.7 ± 50.4), or at daytime (149.3 ± 37.1

2015 Journal of diabetes science and technology Controlled trial quality: uncertain

159. Dose Escalation Trial of Single Subcutaneous Doses of NNC 0113-0217 to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Healthy Male Subjects

hours after dosing ] Area under the curve of NNC 0113-0217 [ Time Frame: From 0-168 hours after dosing ] Morning fasting plasma glucose [ Time Frame: At visit 1 (days -28 to -1), 2 (days 0-8), 3 (days 11-13) and 4 (days 17-19) ] Morning fasting insulin [ Time Frame: At visit 1 (days -28 to -1), 2 (days 0-8), 3 (days 11-13) and 4 (days 17-19) ] Morning fasting glucagon [ Time Frame: At visit 1 (days -28 to -1), 2 (days 0-8), 3 (days 11-13) and 4 (days 17-19) ] Eligibility Criteria Go to Information (...) Dose Escalation Trial of Single Subcutaneous Doses of NNC 0113-0217 to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Healthy Male Subjects Dose Escalation Trial of Single Subcutaneous Doses of NNC 0113-0217 to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Healthy Male Subjects - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x

2017 Clinical Trials

160. Usual Dose Rosuvastatin Plus Ezetimibe Versus High-dose Rosuvastatin on Coronary Atherosclerotic Plaque

Usual Dose Rosuvastatin Plus Ezetimibe Versus High-dose Rosuvastatin on Coronary Atherosclerotic Plaque Usual Dose Rosuvastatin Plus Ezetimibe Versus High-dose Rosuvastatin on Coronary Atherosclerotic Plaque - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100 (...) ). Please remove one or more studies before adding more. Usual Dose Rosuvastatin Plus Ezetimibe Versus High-dose Rosuvastatin on Coronary Atherosclerotic Plaque (Rosuzet-IVUS) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier

2017 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>